Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 août 2023 14h52 HE | Source: Spark Biomedical

Spark Biomedical Awarded $1.15M Department of Defense Phase II STTR Grant in Partnership with Battelle Memorial Institute

DALLAS, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aug. 29, 2023 — Spark Biomedical, Inc., a Dallas-based pioneer in wearable neurostimulation technology, was awarded a $1.15M Phase II grant to...
08 août 2023 12h05 HE | Source: Spark Biomedical

Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment

DALLAS, TX, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment August 8, 2023, Dallas, TX...
11 juil. 2023 14h54 HE | Source: Spark Biomedical

Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults

DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
11 juil. 2023 14h38 HE | Source: Spark Biomedical

Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults

DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
11 juil. 2023 14h31 HE | Source: Spark Biomedical

Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults

DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
06 juil. 2023 14h37 HE | Source: Spark Biomedical

Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand Disease

DALLAS, TX and MANHASSET, NY, July 06, 2023 (GLOBE NEWSWIRE) -- Five Liters, a Dallas-based wearable neuromodulation company, is embarking on a series of groundbreaking first-in-human studies to...
17 janv. 2023 12h47 HE | Source: Spark Biomedical

Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawal

GALVESTON, Texas, Jan. 17, 2023 (GLOBE NEWSWIRE) -- A multi-year clinical trial at the University of Texas Medical Branch (UTMB) and Medical University of South Carolina (MUSC) will examine the use...
02 juin 2022 11h00 HE | Source: Spark Biomedical

Feinstein Institutes for Medical Research and Spark Biomedical, Inc. advance bioelectric medicine designed to stem excessive blood loss

DALLAS, TX and MANHASSET, NY, June 02, 2022 (GLOBE NEWSWIRE) -- Spark Biomedical, a leader in wearable neurostimulation solutions, announced today a collaboration with The Feinstein Institutes for...
03 mars 2022 11h22 HE | Source: Spark Biomedical

Spark Biomedical, Inc., granted $2.49M by the National Institute of Health HEAL Initiative to use neuromodulation as adjunctive therapy for neonatal opioid withdrawal syndrome

Dallas, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Building on Phase I clinical trial success (Jenkins, Khodaparast, et al., 2021), Spark Biomedical, Inc., and The Medical University of South...
16 nov. 2021 11h00 HE | Source: Spark Biomedical

Spark Biomedical, Inc. Granted $2.49M from the National Institutes of Health for a Clinical Trial Looking at Extended Use of Wearable Neurostimulation in Opioid Use Disorder Treatment

Dallas, TX, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. has been helping patients overcome acute opioid withdrawal using its Sparrow Therapy System — Transcutaneous Auricular...

Page précédente

Page suivante